EU Biotech Regulation 2026: What Changed and Who It Affects

The revised General Pharmaceutical Legislation (proposed 2023, political agreement late 2025) is the most concrete 2026 change for pharma R&D. It lowers the baseline regulatory data protection window below the old 8+2-year structure and makes longer protection conditional on earned extensions — launch across member states within a defined window, development for unmet medical need, paediatric investigation, or combination strategies. Orphan and paediatric incentives are restructured in parallel. Environmental risk assessment, antimicrobial pull incentives, and revised shortage-supply obligations also enter the picture. For small and mid-cap biotech, the practical consequence is that investment cases, licensing deals, and in-licensing agreements negotiated in 2026 need to model the new exclusivity math, not the old framework.

EHDS, adopted in 2024, enters application in phases from 2026 through 2029. It has two tracks. Primary use — healthcare delivery — requires Electronic Health Record systems to meet common specifications and support cross-border data sharing via MyHealth@EU. Secondary use — research, policy, statistics — gives qualified data users access to de-identified health data via HealthData@EU and national Health Data Access Bodies. For biotech and pharma, the obligations land in two places: EHR and eHealth product vendors must hit the new specifications and conformity pathways, and companies seeking secondary-use access must register with Health Data Access Bodies and justify purposes under the defined permitted uses. Even if application is years out, vendor selection, data cataloguing, and consent or lawful-basis work begins in 2026.

The AI Act (Regulation (EU) 2024/1689) entered force August 2024 with phased obligations under Article 113. General-purpose AI rules began August 2025. High-risk obligations are the ones that matter most for biotech, and they apply in two tracks. Annex III standalone high-risk systems (biometrics, critical infrastructure, education, employment, law enforcement, etc.) are subject from August 2026. Article 6(1) systems — AI as a safety component of products under EU harmonised legislation, including MDR and IVDR medical devices — are subject from August 2027. That 2027 cohort covers most clinical-grade AI: imaging diagnostics, in-silico stratification, clinical decision support, and AI-enabled medical devices. High-risk providers must operate a risk-management system, enforce data governance and quality, maintain technical documentation, ensure transparency and human oversight, keep logs, and register the system in the EU database. Companies planning 2026–2028 launches of AI-enabled products need the conformity-assessment track decided early in the year.

The Commission’s 2024 Communication on Biotechnology and Biomanufacturing set the priorities the EU Biotech Act is designed to deliver: faster regulatory pathways for biotech products, streamlined environmental risk assessment (including for New Genomic Techniques), scaled EU biomanufacturing capacity, and closing skills and financing gaps. The proposal itself is not law yet and will move through the ordinary legislative procedure before entering force, but the 2024 Communication and national-level implementation work are already shaping permitting, grants, and industrial strategy. Companies in biomanufacturing, NGT-adjacent R&D, and biotech scale-up should track both the Act timeline and national transposition because funding and siting decisions depend on it.

Three concrete moves. First, map every product, pipeline, and platform to the applicable 2026 framework: pharmaceutical legislation (data protection, orphan, paediatric, AMR), MDR/IVDR plus AI Act for device software, EHDS for any data-driven or EHR-adjacent product, and biotech-specific rules for NGTs, advanced therapies, and biomanufacturing. Second, update commercial and clinical plans: modelled exclusivity under the new pharmaceutical math, conformity-assessment routes for AI-enabled devices, and secondary-use data access plans under EHDS. Third, close the documentation gap: quality management systems, technical documentation, data governance, risk-management plans, and environmental risk assessment are moving from optional to required. A directory entry that clearly shows leadership, certifications, and declared compliance systems is now the minimum readable profile the market expects.